The issue’s guest editors resign after falling out with the publisher over the management of papers, including a rejected manuscript on ivermectin, that were submitted for a special issue on drug repurposing for COVID-19.

Increases in the levels of three cytokines are among the features linked to poor outcomes.

YODA, a program facilitated by Yale University researchers, has successfully distributed clinical trial records from Johnson & Johnson and Medtronic to external researchers since 2013.

As the first personalized cell and gene therapies are approved from small clinical trials, researchers propose the creation of publicly accessible databases to pull together real-world results.  

With few resources and hesitant investors, basic scientists must rely on clinicians, patient advocates, and their own keen eye for biological connections.

Teenager Lauren Bendesky turned her cancer diagnosis on its head, using herself as a research subject to test potential therapies.

A study has shown that less than half of the outcomes of some clinical trials are publicly available.

The pharmaceutical industry has agreed to share data from clinical trials with researchers, patients, and the public.

Leading medical and research centers around the world announce a plan to share massive amounts of genetic and clinical information.

NIH Director Francis Collins and colleagues announce plans to create a health-care research network to connect patients, doctors, and clinical researchers.

Despite increasing use of electronic medical records, much patient data remains in text form, requiring text-mining techniques to make full use of patient information.

Tailoring ethical oversight to participant-led research

Although fully organized patient-run trials are still few and far between, patients are taking a more active role in clinical research.

Patients are sidestepping clinical research and using themselves as guinea pigs to test new treatments for fatal diseases. Will they hurt themselves, or science?